Peripheral Artery Disease Market Report 2026

The peripheral artery disease market size has grown strongly in recent years. It will grow from $4.62 billion in 2025 to $4.97 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to high prevalence of peripheral artery disease, limited awareness of PAD risk factors, reliance on traditional medications, inadequate access to interventional specialists, fragmented patient care pathways.

The peripheral artery disease market size is expected to see strong growth in the next few years. It will grow to $6.69 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to advancements in minimally invasive peripheral interventions, growing adoption of drug-eluting balloons and stents, expansion of hospitals and specialty vascular clinics, rising patient awareness and early detection initiatives, increasing use of combination therapies including lifestyle modification and pharmacotherapy. Major trends in the forecast period include increasing use of ai for early pad diagnosis and risk stratification, rising adoption of cloud-based patient monitoring systems, growing focus on genomic-guided personalized pad therapies, increasing integration of iot devices for post-intervention tracking, rising implementation of smart manufacturing in pad device production.

The increasing prevalence of peripheral artery disease is expected to drive the growth of the peripheral artery disease market in the coming years. Peripheral artery disease involves the narrowing or obstruction of arteries outside the heart, most commonly in the legs, which leads to reduced blood flow and an increased risk of complications. Treatment for peripheral artery disease helps alleviate symptoms, improve mobility, and lower the likelihood of serious complications, thereby enhancing patients’ overall quality of life. For instance, in June 2023, according to the American Heart Association, a US-based nonprofit organization, it was estimated that between 7 million and 12 million individuals in the United States and around 200 million people worldwide are affected by peripheral artery disease. Therefore, the rising prevalence of peripheral artery disease is contributing to the growth of the peripheral artery disease market.

Major companies operating in the peripheral artery disease market are concentrating on the development of technologically advanced solutions, such as dissolvable drug-eluting scaffold systems, to address the growing demand for safer, more durable, and minimally invasive treatment options for below-the-knee arterial blockages. These resorbable scaffold technologies are designed to restore blood flow and then gradually dissolve, offering advantages over permanent metallic stents. For example, in April 2024, Abbott Laboratories, a US-based medical device company, launched the Esprit BTK Everolimus Eluting Resorbable Scaffold System, a first-of-its-kind dissolvable stent therapy for below-the-knee peripheral artery disease. The system delivers everolimus to help prevent vessel re-narrowing, while its fully resorbable structure dissolves over time, reducing long-term risks associated with metal implants. It provides physicians with an advanced alternative to traditional angioplasty or permanent stenting, particularly benefiting patients with long lesions or critical limb ischemia. By combining targeted drug delivery with temporary structural support, the Esprit BTK System aims to improve vessel healing, reduce complications, and expand treatment options for complex peripheral artery disease cases.

In April 2023, Abbott Laboratories, a US-based medical device company, acquired Cardiovascular Systems Inc. for an undisclosed amount. Through this acquisition, Abbott expanded and strengthened its peripheral and coronary artery disease portfolio by adding Cardiovascular Systems Inc.’s atherectomy technologies. Cardiovascular Systems Inc. is a US-based medical device company engaged in the development and manufacturing of products for the treatment of peripheral artery disease.

Major companies operating in the peripheral artery disease market are Cardinal Health Inc., Vascular Solutions Inc., Bayer AG, Abbott Laboratories, Medtronic plc., Koninklijke Philips N.V. (Royal Philips), B. Braun Melsungen AG., Terumo Corporation, Edwards Lifesciences, Becton Dickinson and Company (BD), Boston Scientific Corporation Incorporated, Cook Group Incorporated, Merit Medical Systems Inc., NuVasive Inc., Arjo AB, Penumbra Inc., BIOTRONIK SE and Co. KG, AngioDynamics Inc., Shockwave Medical Inc., Cardiovascular Systems Inc., Endologix LLC., LeMaitre Vascular Inc., Silk Road Medical Inc., WL Gore and Associates Inc., MicroPort Scientific Corporation, Bard Peripheral Vascular Inc., Avinger Inc.

North America was the largest region in the peripheral artery disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peripheral artery disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the peripheral artery disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the peripheral artery disease market by raising costs of imported devices, catheters, stents, and drugs, particularly in North America and Europe. This has temporarily slowed adoption in hospitals and specialty clinics, while also encouraging local manufacturing, fostering innovation in cost-efficient PAD devices, and strengthening supply chain resilience for interventional treatments and therapies.

The peripheral artery disease market research report is one of a series of new reports that provides peripheral artery disease market statistics, including peripheral artery disease industry global market size, regional shares, competitors with a peripheral artery disease market share, detailed peripheral artery disease market segments, market trends and opportunities, and any further data you may need to thrive in the peripheral artery disease industry. This peripheral artery disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Peripheral artery disease (PAD) is a condition in which the arteries supplying blood to the limbs, most often the legs, become narrowed or blocked. It is commonly caused by atherosclerosis, a process marked by the buildup of fatty deposits, or plaques, within the arterial walls, leading to reduced blood flow to the affected areas.

The primary products used in the treatment of peripheral artery disease include peripheral angioplasty balloons, peripheral stents, peripheral catheters, inferior vena cava (IVC) filters, plaque modification devices, hemodynamic flow alteration devices, and peripheral accessories. Peripheral angioplasty balloons are medical devices designed to widen narrowed or obstructed peripheral arteries and are used in PAD treatment by inflating the balloon to compress plaque and expand the artery, thereby restoring blood flow. The drugs used for managing PAD include lipid-lowering agents, blood pressure-lowering drugs, glucose-regulating medications, blood clot-preventing drugs, inotropes, thrombolytic agents, and anti-inflammatory agents. These therapies are administered through routes such as oral, parenteral, and others, and are utilized by end users including hospitals, specialty clinics, and others.

The peripheral artery disease market consists of revenues earned by entities by providing peripheral artery disease management services and therapies such as diagnosis, angioplasty, atherectomy, lithoplasty, endovascular, vascular surgery, and rehabilitation. The market value includes the value of related goods sold by the service provider or included within the service offering. The peripheral artery disease market also includes sales of guidewires, bare metal, drug-eluting, compression stockings, and exercise equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.